References
Levien TL, Baker DE, Campbell RK, et al. Nateglinide therapy for type II diabetes mellitus. Ann Pharmacother 2001; 35: 1426–34
Durand JM, Lefevre P, Harle JR, et al. Cutaneous vasculitis and cryoglobulinaemia type II associated with hepatitis C virus infection. Lancet 1991 Feb 23; 337(8739): 499–500
Durand JM, Kaplanski G, Richard MA, et al. Cutaneous vasculitis in a patient infected with hepatitis C virus. Detection of hepatitis C virus RNA in the skin by polymerase chain reaction. Br J Dermatol 1993 Mar; 128(3): 359–60
Pawlotsky JM, Dhumeaux D, Bagot M. Hepatitis C virus in dermatology: a review. Arch Dermatol 1995 Oct; 131(10): 1185–93
Strange P, Schwartz SL, Graf RJ, Polvino W, Weston I, Marbury TC, Huang WC, Goldberg RB. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. Diabetes Technol Ther 1999 Fall; 1(3): 247–56
Hatorp V, Walther KH, Christensen MS, et al. Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. J Clin Pharmacol 2000; 40: 142–52
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Margolin, L. Severe Leucocytoclastic Vasculitis Induced by Repaglinide in a Patient with Chronic Hepatitis C. Clin. Drug Investig. 22, 795–796 (2002). https://doi.org/10.2165/00044011-200222110-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200222110-00008